North America Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Country and Growth Forecast, 2024

List of Tables

The North America Huntington's Disease Treatment Market would witness market growth of 8.5% CAGR during the forecast period (2024-2031).

The US market dominated the North America Huntington's Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $234,802.6 Thousands by 2031. The Canada market is experiencing a CAGR of 10.9% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 9.9% during (2024 - 2031).

Symptomatic management aims to alleviate the motor, cognitive, and psychiatric symptoms associated with Huntington's Disease, thereby improving patients' quality of life. Key therapies include chorea, which is characterized by involuntary movements and is often treated with medications such as tetrabenazine and deutetrabenazine. These drugs help reduce dopamine levels in the brain, mitigating chorea symptoms.

In addition, muscle rigidity and dystonia, which can cause discomfort and impair movement, may be managed with muscle relaxants and physical therapy. HD patients commonly experience psychiatric disturbances like depression, anxiety, and irritability. Antidepressants, anxiolytics, and antipsychotic medications are prescribed to manage these symptoms. While specific medications for cognitive decline in HD are limited, cognitive rehabilitation, memory aids, and supportive therapies play a crucial role in managing cognitive impairments.

Rare diseases often present diagnostic challenges due to their unfamiliarity among healthcare providers. The burden of these disorders on patients and their families may increase because of delays in diagnosis and necessary treatment. The Canadian government reports that of the more than 7,000 identified rare diseases, 14,000 children under the age of 15 in Canada pass away from a rare disease annually. Furthermore, increased funding can lead to establishing or expanding research facilities and laboratories specializing in neurodegenerative diseases like HD. This infrastructure supports advanced research methodologies and recruiting specialized researchers and clinicians. Canada's first National Strategy for Drugs for Rare Diseases, unveiled in March 2023, aims to increase the availability and cost-effectiveness of drugs for rare diseases. In addition, higher healthcare expenditure in Mexico facilitates greater accessibility to specialized neurology services, including diagnostic facilities, neurological consultations, and multidisciplinary care teams equipped to manage complex conditions like Huntington's Disease. Thus, the high prevalence of rare diseases and rising healthcare expenditure in the region is driving the growth of the market.

Based on Drug Type, the market is segmented into Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Pharmacies. Based on Age, the market is segmented into Below 50 years and Above 50 years. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

Bausch Health Companies, Inc.
Teva Pharmaceutical Industries Ltd.
Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
Hikma Pharmaceuticals PLC
Takeda Pharmaceutical Company Limited
Sun Pharmaceutical Industries Ltd.
Dr. Reddy's Laboratories Ltd.
Neurocrine Biosciences Inc.
Pfizer, Inc.
F. Hoffmann-La Roche Ltd.

North America Huntington's Disease Treatment Market Report Segmentation

By Drug Type

Approved Drugs
- Tetrabenazine
- Deutetrabenazine
Offlabel Drugs

By Distribution Channel

Hospital Pharmacies
Drug Store & Retail Pharmacies
Online Pharmacies

By Age

Below 50 years
Above 50 years

By Country

US
Canada
Mexico
Rest of North America

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 North America Huntington's Disease Treatment Market, by Drug Type
- 1.4.2 North America Huntington's Disease Treatment Market, by Distribution Channel
- 1.4.3 North America Huntington's Disease Treatment Market, by Age
- 1.4.4 North America Huntington's Disease Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
- 3.2.3 Market Opportunities
- 3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. North America Huntington's Disease Treatment Market by Drug Type

4.1 North America Approved Drugs Market by Region
4.2 North America Huntington's Disease Treatment Market by Approved Drugs Type
- 4.2.1 North America Tetrabenazine Market by Country
- 4.2.2 North America Deutetrabenazine Market by Country
4.3 North America Offlabel Drugs Market by Region

Chapter 5. North America Huntington's Disease Treatment Market by Distribution Channel

5.1 North America Hospital Pharmacies Market by Country
5.2 North America Drug Store & Retail Pharmacies Market by Country
5.3 North America Online Pharmacies Market by Country

Chapter 6. North America Huntington's Disease Treatment Market by Age

6.1 North America Below 50 years Market by Country
6.2 North America Above 50 years Market by Country

Chapter 7. North America Huntington's Disease Treatment Market by Country

7.1 US Huntington's Disease Treatment Market
- 7.1.1 US Huntington's Disease Treatment Market by Drug Type
  - 7.1.1.1 US Huntington's Disease Treatment Market by Approved Drugs Type
- 7.1.2 US Huntington's Disease Treatment Market by Distribution Channel
- 7.1.3 US Huntington's Disease Treatment Market by Age
7.2 Canada Huntington's Disease Treatment Market
- 7.2.1 Canada Huntington's Disease Treatment Market by Drug Type
  - 7.2.1.1 Canada Huntington's Disease Treatment Market by Approved Drugs Type
- 7.2.2 Canada Huntington's Disease Treatment Market by Distribution Channel
- 7.2.3 Canada Huntington's Disease Treatment Market by Age
7.3 Mexico Huntington's Disease Treatment Market
- 7.3.1 Mexico Huntington's Disease Treatment Market by Drug Type
  - 7.3.1.1 Mexico Huntington's Disease Treatment Market by Approved Drugs Type
- 7.3.2 Mexico Huntington's Disease Treatment Market by Distribution Channel
- 7.3.3 Mexico Huntington's Disease Treatment Market by Age
7.4 Rest of North America Huntington's Disease Treatment Market
- 7.4.1 Rest of North America Huntington's Disease Treatment Market by Drug Type
  - 7.4.1.1 Rest of North America Huntington's Disease Treatment Market by Approved Drugs Type
- 7.4.2 Rest of North America Huntington's Disease Treatment Market by Distribution Channel
- 7.4.3 Rest of North America Huntington's Disease Treatment Market by Age

Chapter 8. Company Profiles

8.1 Dr. Reddy's Laboratories Ltd.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Segmental and Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 SWOT Analysis
8.2 Takeda Pharmaceutical Company Limited
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expense
- 8.2.5 SWOT Analysis
8.3 Sun Pharmaceutical Industries Ltd.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expenses
- 8.3.5 SWOT Analysis
8.4 Hikma Pharmaceuticals PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Segmental and Regional Analysis
- 8.4.4 Research & Development Expenses
8.5 Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
- 8.5.1 Company Overview
8.6 Teva Pharmaceutical Industries Ltd.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Regional Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 SWOT Analysis
8.7 Bausch Health Companies, Inc
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental and Regional Analysis
- 8.7.4 Research & Development Expense
- 8.7.5 SWOT Analysis
8.8 Neurocrine Biosciences Inc.
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Research & Development Expenses
8.9 Pfizer, Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Regional & Segmental Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 SWOT Analysis
8.10. F. Hoffmann-La Roche Ltd.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Segmental and Regional Analysis
- 8.10.4 Research & Development Expense
- 8.10.5 SWOT Analysis

LIST OF TABLES

TABLE 1 North America Huntington's Disease Treatment Market, 2020 - 2023, USD Thousands
TABLE 2 North America Huntington's Disease Treatment Market, 2024 - 2031, USD Thousands
TABLE 3 North America Huntington's Disease Treatment Market by Drug Type, 2020 - 2023, USD Thousands
TABLE 4 North America Huntington's Disease Treatment Market by Drug Type, 2024 - 2031, USD Thousands
TABLE 5 North America Approved Drugs Market by Region, 2020 - 2023, USD Thousands
TABLE 6 North America Approved Drugs Market by Region, 2024 - 2031, USD Thousands
TABLE 7 North America Huntington's Disease Treatment Market by Approved Drugs Type, 2020 - 2023, USD Thousands
TABLE 8 North America Huntington's Disease Treatment Market by Approved Drugs Type, 2024 - 2031, USD Thousands
TABLE 9 North America Tetrabenazine Market by Country, 2020 - 2023, USD Thousands
TABLE 10 North America Tetrabenazine Market by Country, 2024 - 2031, USD Thousands
TABLE 11 North America Deutetrabenazine Market by Country, 2020 - 2023, USD Thousands
TABLE 12 North America Deutetrabenazine Market by Country, 2024 - 2031, USD Thousands
TABLE 13 North America Offlabel Drugs Market by Region, 2020 - 2023, USD Thousands
TABLE 14 North America Offlabel Drugs Market by Region, 2024 - 2031, USD Thousands
TABLE 15 North America Huntington's Disease Treatment Market by Distribution Channel, 2020 - 2023, USD Thousands
TABLE 16 North America Huntington's Disease Treatment Market by Distribution Channel, 2024 - 2031, USD Thousands
TABLE 17 North America Hospital Pharmacies Market by Country, 2020 - 2023, USD Thousands
TABLE 18 North America Hospital Pharmacies Market by Country, 2024 - 2031, USD Thousands
TABLE 19 North America Drug Store & Retail Pharmacies Market by Country, 2020 - 2023, USD Thousands
TABLE 20 North America Drug Store & Retail Pharmacies Market by Country, 2024 - 2031, USD Thousands
TABLE 21 North America Online Pharmacies Market by Country, 2020 - 2023, USD Thousands
TABLE 22 North America Online Pharmacies Market by Country, 2024 - 2031, USD Thousands
TABLE 23 North America Huntington's Disease Treatment Market by Age, 2020 - 2023, USD Thousands
TABLE 24 North America Huntington's Disease Treatment Market by Age, 2024 - 2031, USD Thousands
TABLE 25 North America Below 50 years Market by Country, 2020 - 2023, USD Thousands
TABLE 26 North America Below 50 years Market by Country, 2024 - 2031, USD Thousands
TABLE 27 North America Above 50 years Market by Country, 2020 - 2023, USD Thousands
TABLE 28 North America Above 50 years Market by Country, 2024 - 2031, USD Thousands
TABLE 29 North America Huntington's Disease Treatment Market by Country, 2020 - 2023, USD Thousands
TABLE 30 North America Huntington's Disease Treatment Market by Country, 2024 - 2031, USD Thousands
TABLE 31 US Huntington's Disease Treatment Market, 2020 - 2023, USD Thousands
TABLE 32 US Huntington's Disease Treatment Market, 2024 - 2031, USD Thousands
TABLE 33 US Huntington's Disease Treatment Market by Drug Type, 2020 - 2023, USD Thousands
TABLE 34 US Huntington's Disease Treatment Market by Drug Type, 2024 - 2031, USD Thousands
TABLE 35 US Huntington's Disease Treatment Market by Approved Drugs Type, 2020 - 2023, USD Thousands
TABLE 36 US Huntington's Disease Treatment Market by Approved Drugs Type, 2024 - 2031, USD Thousands
TABLE 37 US Huntington's Disease Treatment Market by Distribution Channel, 2020 - 2023, USD Thousands
TABLE 38 US Huntington's Disease Treatment Market by Distribution Channel, 2024 - 2031, USD Thousands
TABLE 39 US Huntington's Disease Treatment Market by Age, 2020 - 2023, USD Thousands
TABLE 40 US Huntington's Disease Treatment Market by Age, 2024 - 2031, USD Thousands
TABLE 41 Canada Huntington's Disease Treatment Market, 2020 - 2023, USD Thousands
TABLE 42 Canada Huntington's Disease Treatment Market, 2024 - 2031, USD Thousands
TABLE 43 Canada Huntington's Disease Treatment Market by Drug Type, 2020 - 2023, USD Thousands
TABLE 44 Canada Huntington's Disease Treatment Market by Drug Type, 2024 - 2031, USD Thousands
TABLE 45 Canada Huntington's Disease Treatment Market by Approved Drugs Type, 2020 - 2023, USD Thousands
TABLE 46 Canada Huntington's Disease Treatment Market by Approved Drugs Type, 2024 - 2031, USD Thousands
TABLE 47 Canada Huntington's Disease Treatment Market by Distribution Channel, 2020 - 2023, USD Thousands
TABLE 48 Canada Huntington's Disease Treatment Market by Distribution Channel, 2024 - 2031, USD Thousands
TABLE 49 Canada Huntington's Disease Treatment Market by Age, 2020 - 2023, USD Thousands
TABLE 50 Canada Huntington's Disease Treatment Market by Age, 2024 - 2031, USD Thousands
TABLE 51 Mexico Huntington's Disease Treatment Market, 2020 - 2023, USD Thousands
TABLE 52 Mexico Huntington's Disease Treatment Market, 2024 - 2031, USD Thousands
TABLE 53 Mexico Huntington's Disease Treatment Market by Drug Type, 2020 - 2023, USD Thousands
TABLE 54 Mexico Huntington's Disease Treatment Market by Drug Type, 2024 - 2031, USD Thousands
TABLE 55 Mexico Huntington's Disease Treatment Market by Approved Drugs Type, 2020 - 2023, USD Thousands
TABLE 56 Mexico Huntington's Disease Treatment Market by Approved Drugs Type, 2024 - 2031, USD Thousands
TABLE 57 Mexico Huntington's Disease Treatment Market by Distribution Channel, 2020 - 2023, USD Thousands
TABLE 58 Mexico Huntington's Disease Treatment Market by Distribution Channel, 2024 - 2031, USD Thousands
TABLE 59 Mexico Huntington's Disease Treatment Market by Age, 2020 - 2023, USD Thousands
TABLE 60 Mexico Huntington's Disease Treatment Market by Age, 2024 - 2031, USD Thousands
TABLE 61 Rest of North America Huntington's Disease Treatment Market, 2020 - 2023, USD Thousands
TABLE 62 Rest of North America Huntington's Disease Treatment Market, 2024 - 2031, USD Thousands
TABLE 63 Rest of North America Huntington's Disease Treatment Market by Drug Type, 2020 - 2023, USD Thousands
TABLE 64 Rest of North America Huntington's Disease Treatment Market by Drug Type, 2024 - 2031, USD Thousands
TABLE 65 Rest of North America Huntington's Disease Treatment Market by Approved Drugs Type, 2020 - 2023, USD Thousands
TABLE 66 Rest of North America Huntington's Disease Treatment Market by Approved Drugs Type, 2024 - 2031, USD Thousands
TABLE 67 Rest of North America Huntington's Disease Treatment Market by Distribution Channel, 2020 - 2023, USD Thousands
TABLE 68 Rest of North America Huntington's Disease Treatment Market by Distribution Channel, 2024 - 2031, USD Thousands
TABLE 69 Rest of North America Huntington's Disease Treatment Market by Age, 2020 - 2023, USD Thousands
TABLE 70 Rest of North America Huntington's Disease Treatment Market by Age, 2024 - 2031, USD Thousands
TABLE 71 Key Information - Dr. Reddy's Laboratories Ltd.
TABLE 72 Key Information - Takeda Pharmaceutical Company Limited
TABLE 73 Key Information - Sun Pharmaceutical Industries Ltd.
TABLE 74 Key Information - Hikma Pharmaceuticals PLC
TABLE 75 Key Information - Camber Pharmaceuticals, Inc.
TABLE 76 Key Information - Teva Pharmaceuticals Industries Ltd.
TABLE 77 key information - Bausch Health Companies, Inc.
TABLE 78 Key Information - Neurocrine Biosciences Inc.
TABLE 79 Key Information - Pfizer, Inc.
TABLE 80 Key Information - F. Hoffmann-La Roche Ltd.

North America Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Type (Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs), By Distribution Channel, By Age, By Country and Growth Forecast, 2024 - 2031

Description

Table of Contents